Mostrar el registro sencillo del ítem

dc.contributor.authorVazquez-Moron, Sonia 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorCanorea, Isabel 
dc.contributor.authorGuardiola, Josep M
dc.contributor.authorCrespo, Manuel
dc.contributor.authorQuereda, Carmen
dc.contributor.authorSanz, José
dc.contributor.authorCarrero, Ana
dc.contributor.authorHontañón, Victor
dc.contributor.authorAvellón, Ana 
dc.contributor.authorResino, Salvador 
dc.date.accessioned2019-04-10T11:39:35Z
dc.date.available2019-04-10T11:39:35Z
dc.date.issued2019-02-04
dc.identifier.citationSci Rep. 2019 Feb 4;9(1):1143.es_ES
dc.identifier.issn2045-2322es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7444
dc.description.abstractHepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to determine the prevalence of anti-HEV antibodies, acute hepatitis E, resolved hepatitis E, and exposure to HEV in HIV/HCV-coinfected patients and to evaluate associations with clinical and epidemiological characteristics. We performed a cross-sectional study on 198 HIV/HCV-coinfected patients, 30 healthy controls and 36 HIV-monoinfected patients. We found a low concordance between techniques used for detection of anti-HEV antibodies (ELISA versus Immunoblot), particularly in HIV/HCV-coinfected patients. HIV/HCV-coinfected patients showed the highest prevalence of IgG against HEV, resolved hepatitis E, and exposure to HEV (19.2%, 17.2%, and 22.2% respectively). However, we did not find any samples positive for HEV-RNA nor significant differences between groups. Moreover, HIV/HCV-coinfected patients with CD4 T-cells <350 cells/mm3 had higher prevalence for anti-HEV IgG antibodies, resolved hepatitis E, and exposure to HEV than healthy controls or those with CD4 T-cells ≥ 350 cells/mm3 (p = 0.034, p = 0.035, and p = 0.053; respectively). In conclusion, HIV/HCV-coinfected patients in Spain have a high prevalence for IgG anti-HEV antibodies, resolved hepatitis E, and exposure to HEV; particularly patients with CD4+T-cells <350 cells/mm3.es_ES
dc.description.sponsorshipThe HIV BioBank, integrated in the Spanish AIDS Research Network, is supported by the Institute of Health Carlos III, ISCIII, Spanish Health Ministry (Grant n° RD06/0006/0035 and RD12/0017/0037) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF) and Foundation for Research and Prevention of AIDS in Spain (FIPSE). The RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) as part of the State Plan for Scientific and Technical Research and Innovation and co-financed by ISCIII- Sub-Directorate General for Research Assessment and Promotion and European Regional Development Fund (ERDF). This study was supported by grants from Instituto de Salud Carlos III (ISCII; grant numbers grant numbers PI14/01094 and PI17/00657 to JB, PI14/01581, and PI17/00903 to JGG, PI14CIII/00011, and PI17CIII/00003 to SR), Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11–241). The RD16CIII/0002/0002, RD16/0025/0017, and RD16/0025/0018 projects also funded the study as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Group es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titlePrevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012-2014)es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30718554es_ES
dc.format.volume9es_ES
dc.format.number1es_ES
dc.format.page1143es_ES
dc.identifier.doi10.1038/s41598-018-37328-6es_ES
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España 
dc.contributor.funderMinisterio de Sanidad, Servicios Sociales e Igualdad (España) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-018-37328-6es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01094es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00657es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01581es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17/00903es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI17CIII/00003es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/EC11–241es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0017es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0018es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional